Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp-erzs (SL-401) as consolidation therapy for AML
NCT02270463Phase 2Terminated
- Sponsor
- Stemline Therapeutics
- Start
- Feb 2015
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
A Phase 2 trial of tagraxofusp in acute myeloid leukemia (AML), sponsored by Stemline Therapeutics. Started Feb 2015; status: terminated.
02
Drugs
tagraxofusp
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02270463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02270463.